Showcasing cutting-edge targeting formats and payload innovations designed to improve delivery, overcome resistance, and broaden the therapeutic potential of next-generation treatments across challenging disease areas.
Novel conjugates are rapidly emerging as one of the most competitive frontiers in precision oncology. With companies advancing beyond traditional ADCs, the focus is shifting toward new payload mechanisms and differentiated targeting formats to overcome resistance, widen therapeutic windows, address ADC-refractory cancers, and expand into non-oncology indications. The 5th Novel Conjugates Summit is the only industry meeting dedicated to offering deep insight into the most promising approaches, their advantages, and the future direction of this fast-evolving field.
View Event
